Bloch Fleshes Out Long-term NSF Budget

WASHINGTON—Director Erich Bloch, under congressional prodding last month, predicted that the National Science Foundation will come to grips in the next five years with many of the major problems facing American science. Bloch used the annual round of hearings on NSF's request for funding to flesh out the administration's wish to double the agency's budget, to $3.2 billion, by 1992. That financial goal is part of an attempt by Bloch, a former IBM vice president, to graft a corporate approac

Written byJeffrey Mervis
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Bloch used the annual round of hearings on NSF's request for funding to flesh out the administration's wish to double the agency's budget, to $3.2 billion, by 1992. That financial goal is part of an attempt by Bloch, a former IBM vice president, to graft a corporate approach to long-range planning onto an agency that must delay final decisions until Congress approves its budget each fall.

The atmosphere surrounding Bloch's testimony before the House subcommittee that authorizes the NSF's budget was noticeably warmer than the combative air marking his appearances before the appropriations panels. In gentle questioning by panel chairman Rep. Doug Waigren (D-Pa.), Bloch spelled out in unusual detail his image of NSF if its budget were doubled by 1992. He noted that its initial request to the Office of Management and Budget was for a 33 percent increase next year, and a doubling within three years.

"I hope ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies